VeriSilicon and Innobase Collaboratively Launched Second-Generation Yunbao Series 5G RedCap/4G LTE Dual-Mode Modem IP
23.1.2025 01:00:00 CET | Business Wire | Press release
Advancing cellular mobile communication technology innovation and accelerating the lightweight 5G application adoption
VeriSilicon (688521.SH) today announced the joint launch of the second-generation Yunbao series 5G RedCap/4G LTE dual-mode modem IP, Yunbao 2, in collaboration with Innobase, a wireless communication technology and chip provider. This new modem IP has successfully completed production validation.
The newly launched modem IP integrates and reuses 4G and 5G hardware accelerators, delivering industry-leading performance in terms of area and power consumption. This IP complies with the 3GPP 5G Rel-17 standard and supports both 5G RedCap and 4G LTE FDD/TDD, achieving uplink and downlink transmission rates of 170 Mbps and 120 Mbps, respectively. It also supports multi-SIM standby and features key 5G capabilities such as Ultra-Reliable Low Latency Communication (URLLC), 5G LAN, and network slicing. Furthermore, chips developed using the Yunbao 2 modem IP can be paired with Innobase’s production-validated high-performance dual-mode RF chips, enabling seamless product-level integration and significantly accelerating the commercialization process for customers.
Under the guidance and organization of the IMT-2020 (5G) Promotion Group, the Yunbao series has successfully completed 5G RedCap terminal equipment and field performance testing with Nokia Shanghai Bell and ZTE. Additionally, it has completed interoperation tests between 5G RedCap terminals and base stations in collaboration with partners. These tests were conducted strictly adhering to the standards set by the Promotion Group, covering the full range of 5G RedCap terminal functionalities and performance metrics. The results thoroughly validated the overall capabilities of the Yunbao series, as well as its seamless interoperability with multiple network equipment vendors.
“The commercialization of RedCap in China has entered a rapid growth phase. As a new 5G variant defined under the 3GPP Rel-17 standard, RedCap features low cost, low latency, private network, and efficient spectrum utilization, making it an ideal solution for wearable devices, industrial IoT, and mass-market smartphones,” said Lu Wenbo, Senior Vice President of Innobase. “Innobase has introduced a variety of mass-production-ready products, including 5G IoT modules, MiFi devices, and mass-market 5G smartphones, which have successfully validated the Yunbao series IP at the product level. In the future, Innobase will leverage its extensive expertise in cellular communication technologies to develop the Yunbao X series featuring ultra-low-cost and ultra-low-power designs, to address the needs of consumer electronics and IoT applications. With the RedCap market rapidly evolving, we are excited to collaborate with VeriSilicon to deliver more advanced 5G multi-mode modem IP solutions to our customers.”
“The cost and performance of 5G RedCap chips are comparable to those of 4G, further expanding the boundaries of existing 4G application scenarios,” said Wiseway Wang, Executive Vice President, General Manager of Custom Silicon Platform Division of VeriSilicon. “Through our collaboration with Innobase, VeriSilicon is able to offer production-validated 4G/5G RedCap dual-mode IPs, further strengthening our existing IP ecosystem. VeriSilicon remains committed to driving innovation in low-power, high-performance wireless communication technologies, providing comprehensive wireless communication solutions, including RF, baseband, and protocol stacks, for IoT applications. Looking ahead, VeriSilicon will continue working closely with industry partners to build a global cellular communication ecosystem and contribute to an intelligent, connected future.”
About Innobase
Innobase is a leading fabless chip design company for cellular mobile communications. It designs chipset of 4G/5G and future 6G, including Baseband, RF, and PMIC for mobile terminals. Its dual mode chipset of 4G LTE/5G RedCap is commercialized with customers including telecom operators, IoT module makers, and mobile phone IDHs/ODMs. For more information, please visit: www.innobase.com.cn
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121582002/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom